Eline Op de Coul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eline Op de Coul has a total of 368 co-authors. Here are the top co-authors by number of shared publications:
- Hannelore Martha Götz
Department of Public Health, GGD Rotterdam-Rijnmond, Rotterdam, Netherlands
9 shared publications - Birgit H. B. van Benthem
Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands
6 shared publications - Chantal Den Daas
Health Psychology Group Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
6 shared publications - Ard van Sighem
Stichting HIV Monitoring, Amsterdam, The Netherlands
5 shared publications - Christian Jean Pierre Antoine Hoebe
Department of Social Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
5 shared publications - Maria Xiridou
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
5 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (37) , 2600048
Identifying socioeconomic characteristics of pregnant women aged 15–50 years diagnosed with HIV during pregnancy, the Netherlands, 2016 to 2023
BACKGROUND: Pregnant women in the Netherlands are screened for HIV during the first trimester. Insight into characteristics of women diagnosed with HIV may help identify groups who could benefit from testing strategies. AIM: We assessed the contribution of HIV diagnoses during pregnancy to the total number of diagnoses among women in the Netherlands between 2016 and 2023 and identified socioeconomic characteristics of women with an antenatal diagnosis. METHODS: In a cross-sectional analysis, we selected women aged 15–50 years registered in the national ATHENA cohort and diagnosed with HIV in the Netherlands. Each pregnant woman with HIV was matched by year of pregnancy to three pregnant women without HIV from the general population using non-public registry data from Statistics Netherlands. Characteristics were examined using multivariable logistic regression. RESULTS: Ninety-two of 523 women with HIV were diagnosed during pregnancy. These women less often had an advanced HIV infection than non-pregnant women with HIV (22 vs. 47%). Eighty-three of 92 pregnant women with HIV were matched with 249 pregnant women without HIV. Being diagnosed during pregnancy was associated with first- (aOR: 14.1; 95% CI: 6.45–30.6) or second-generation migration background (aOR: 5.38; 95% CI:2.02–11.0), income below the poverty line (aOR: 3.46; 95% CI: 1.28–9.34) and living in a single-parent household (aOR: 3.46; 95% CI: 1.52–7.88). CONCLUSION: Antenatal HIV diagnoses accounted for a substantial part of diagnoses among women; pregnant women were less likely to present with advanced-stage disease. These findings show the importance of universal antenatal HIV screening.
- 17 September 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (37) , 2600048
Open AccessIdentifying socioeconomic characteristics of pregnant women aged 15–50 years diagnosed with HIV during pregnancy, the Netherlands, 2016 to 2023
BACKGROUND: Pregnant women in the Netherlands are screened for HIV during the first trimester. Insight into characteristics of women diagnosed with HIV may help identify groups who could benefit from testing strategies. AIM: We assessed the contribution of HIV diagnoses during pregnancy to the total number of diagnoses among women in the Netherlands between 2016 and 2023 and identified socioeconomic characteristics of women with an antenatal diagnosis. METHODS: In a cross-sectional analysis, we selected women aged 15–50 years registered in the national ATHENA cohort and diagnosed with HIV in the Netherlands. Each pregnant woman with HIV was matched by year of pregnancy to three pregnant women without HIV from the general population using non-public registry data from Statistics Netherlands. Characteristics were examined using multivariable logistic regression. RESULTS: Ninety-two of 523 women with HIV were diagnosed during pregnancy. These women less often had an advanced HIV infection than non-pregnant women with HIV (22 vs. 47%). Eighty-three of 92 pregnant women with HIV were matched with 249 pregnant women without HIV. Being diagnosed during pregnancy was associated with first- (aOR: 14.1; 95% CI: 6.45–30.6) or second-generation migration background (aOR: 5.38; 95% CI:2.02–11.0), income below the poverty line (aOR: 3.46; 95% CI: 1.28–9.34) and living in a single-parent household (aOR: 3.46; 95% CI: 1.52–7.88). CONCLUSION: Antenatal HIV diagnoses accounted for a substantial part of diagnoses among women; pregnant women were less likely to present with advanced-stage disease. These findings show the importance of universal antenatal HIV screening.
- Open Access
- 13 August 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (32) , 2500921
Multi-country study on the impact of a revised consensus definition of late HIV diagnosis, Europe, 2022 to 2023
BACKGROUND: With improvements in test sensitivity and testing frequency, more people in Europe are diagnosed during the HIV acute/seroconversion phase, when their CD4 + T-cell count can be temporarily low. AIM: We piloted a revised definition of late HIV diagnosis for surveillance which considers laboratory markers, evidence of HIV test negativity in the past year and clinical evidence of recent HIV acquisition, to better distinguish between people diagnosed late and those diagnosed during the acute/seroconversion phase. METHODS: We collected pseudonymised HIV diagnosis records for 2022 and 2023 from nine European countries (Belgium, Czechia, Denmark, Germany, Greece, Italy, the Netherlands, Portugal and Sweden). We applied the revised definition to reclassify those with evidence of recently acquired HIV as 'not late' and calculated the corresponding correction factor by country and demographic group. Individuals with a previous diagnosis were excluded from the analysis. RESULTS: Among 10,220 individuals with a CD4 + T-cell count at diagnosis, 56% (5,689/10,220) had a CD4 + T-cell count < 350 cells/µL or an AIDS-defining event at diagnosis. Applying the revised definition reduced the late diagnosis proportion from 56% to 50%, a correction factor of 9% (535/5,689). The correction factor ranged between 3% and 25% across countries and was higher for younger ages and for gay, bisexual and other men who have sex with men, compared with other groups. CONCLUSIONS: Without reclassification, late HIV diagnosis proportions are overestimated. We provide recommendations and validity considerations for countries intending to use the revised definition.
- 13 August 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (32) , 2500921
Open AccessMulti-country study on the impact of a revised consensus definition of late HIV diagnosis, Europe, 2022 to 2023
BACKGROUND: With improvements in test sensitivity and testing frequency, more people in Europe are diagnosed during the HIV acute/seroconversion phase, when their CD4 + T-cell count can be temporarily low. AIM: We piloted a revised definition of late HIV diagnosis for surveillance which considers laboratory markers, evidence of HIV test negativity in the past year and clinical evidence of recent HIV acquisition, to better distinguish between people diagnosed late and those diagnosed during the acute/seroconversion phase. METHODS: We collected pseudonymised HIV diagnosis records for 2022 and 2023 from nine European countries (Belgium, Czechia, Denmark, Germany, Greece, Italy, the Netherlands, Portugal and Sweden). We applied the revised definition to reclassify those with evidence of recently acquired HIV as 'not late' and calculated the corresponding correction factor by country and demographic group. Individuals with a previous diagnosis were excluded from the analysis. RESULTS: Among 10,220 individuals with a CD4 + T-cell count at diagnosis, 56% (5,689/10,220) had a CD4 + T-cell count < 350 cells/µL or an AIDS-defining event at diagnosis. Applying the revised definition reduced the late diagnosis proportion from 56% to 50%, a correction factor of 9% (535/5,689). The correction factor ranged between 3% and 25% across countries and was higher for younger ages and for gay, bisexual and other men who have sex with men, compared with other groups. CONCLUSIONS: Without reclassification, late HIV diagnosis proportions are overestimated. We provide recommendations and validity considerations for countries intending to use the revised definition.
- Open Access
- 9 April 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (14) , 2500322
Use of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022
BACKGROUND: Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations. AIM: We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS: We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points. RESULTS: Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM. DISCUSSION: Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.
- 9 April 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (14) , 2500322
Open AccessUse of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022
BACKGROUND: Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations. AIM: We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS: We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points. RESULTS: Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM. DISCUSSION: Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.
- Open Access
- 25 January 2025
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-11
Self-sampling and self-testing for HIV at a commercial and community-based test provider in the Netherlands: user preferences and usability
HIV self-sampling and -testing (HIVSS/ST) reduces testing barriers and potentially reaches populations who may not test otherwise. In the Netherlands, at-home HIV tests became commercially available around 2016, but data on user experiences are limited. This study aimed to explore characteristics of users and their experiences with HIVSS/ST. In 2022 and 2023, a survey was distributed among users of one online commercial provider and one community-based provider; either users ordered a commercial online HIVSS/ST or they sought a free-of-charge HIVST via the community-based provider. Questions included usability, preferences, and barriers of HIVSS/ST-testing. We compared characteristics and experiences of users between providers, risk groups and first-time and repeat testers. In total, 133 users completed the survey; 89 (67%) via the commercial provider and 44 (33%) via the community-based provider. Response rates per provider were 2% and 26%, respectively. Users who bought their test at the commercial provider were more often Gay and Bisexual Men (GBM) (42%), 35 + years (43%), and born in the Netherlands (89%), compared to those recruited through the community-provider (respectively 27%, 25%, 14%). GBM were more often repeat and recent HIVSS/ST-testers, and using pre-exposure prophylaxis (PrEP). Women and heterosexual men were more likely to buy an HIVSS/ST as part of a combination Sexually Transmitted Infections (STI) test package. Overall, main reasons for choosing HIVSS/ST were saving time (42%), anonymity (36%) and not having to talk to a GP (35%). Twenty-two percent of the study participants experienced some problems performing the HIVSS/ST, the most reported problem was obtaining sufficient blood through the finger prick (71%). Recommendations to improve accessibility of HIVSS/ST included more awareness (advertising by trustful providers), more access locations (pharmacies/supermarkets/schools) and lower costs. Our findings indicate that HIVSS/ST is a valuable additional HIV testing method for users, but more insight into the contribution of HIVSS/ST to HIV prevention policies is needed.
- 25 January 2025
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-11
Open AccessSelf-sampling and self-testing for HIV at a commercial and community-based test provider in the Netherlands: user preferences and usability
HIV self-sampling and -testing (HIVSS/ST) reduces testing barriers and potentially reaches populations who may not test otherwise. In the Netherlands, at-home HIV tests became commercially available around 2016, but data on user experiences are limited. This study aimed to explore characteristics of users and their experiences with HIVSS/ST. In 2022 and 2023, a survey was distributed among users of one online commercial provider and one community-based provider; either users ordered a commercial online HIVSS/ST or they sought a free-of-charge HIVST via the community-based provider. Questions included usability, preferences, and barriers of HIVSS/ST-testing. We compared characteristics and experiences of users between providers, risk groups and first-time and repeat testers. In total, 133 users completed the survey; 89 (67%) via the commercial provider and 44 (33%) via the community-based provider. Response rates per provider were 2% and 26%, respectively. Users who bought their test at the commercial provider were more often Gay and Bisexual Men (GBM) (42%), 35 + years (43%), and born in the Netherlands (89%), compared to those recruited through the community-provider (respectively 27%, 25%, 14%). GBM were more often repeat and recent HIVSS/ST-testers, and using pre-exposure prophylaxis (PrEP). Women and heterosexual men were more likely to buy an HIVSS/ST as part of a combination Sexually Transmitted Infections (STI) test package. Overall, main reasons for choosing HIVSS/ST were saving time (42%), anonymity (36%) and not having to talk to a GP (35%). Twenty-two percent of the study participants experienced some problems performing the HIVSS/ST, the most reported problem was obtaining sufficient blood through the finger prick (71%). Recommendations to improve accessibility of HIVSS/ST included more awareness (advertising by trustful providers), more access locations (pharmacies/supermarkets/schools) and lower costs. Our findings indicate that HIVSS/ST is a valuable additional HIV testing method for users, but more insight into the contribution of HIVSS/ST to HIV prevention policies is needed.
- Open Access
Combining mpox vaccination and behavioural changes to control possible future mpox resurgence among men who have sex with men: a mathematical modelling study
Introduction: The 2022 outbreak of mpox subclade IIb in the Netherlands affected primarily men who have sex with men (MSM). Despite the sharp decline in cases, there are concerns about future mpox outbreaks. We investigated the impact of mpox introductions, accounting for vaccination, behavioural changes, and introductions of subclades with different characteristics. Methods: We developed a compartmental model for mpox among MSM. We distinguished three levels of sexual activity: low, medium, and high. The group with high activity was the 5% of the population with the highest numbers of sexual partners; the group with low activity was the 60% with the lowest numbers of partners. In the model, individuals were allowed to change sexual activity level. We examined several scenarios with mpox introductions. Results: In January 2024, 54% of MSM with high sexual activity level had immunity; this declined to 39% a year later, due to changes in sexual activity. Introduction of 5 cases in May 2025 resulted in 759 cases in the first four months without vaccination after 2023, but the numbers of cases were 34% or 48% lower with 3,000 vaccinations in August-October 2024 or February-April 2025, respectively. With earlier initiation or greater magnitude of behavioural adaptations, the number of mpox cases was 17-51% smaller. Introduction of a subclade with 10% higher transmission probability than subclade IIb resulted in 77% more cases. Conclusions: Due to changes in sexual activity, the fraction immune in the group with high sexual activity will decline, leading to greater possibilities for future mpox outbreaks. The number of cases can be reduced with preventive vaccination and behavioural adaptations. Recurring vaccination campaigns should prioritise individuals with high sexual activity level, ensuring those entering high-activity groups are reached. Campaigns promoting timely behavioural changes remain crucial. KEY MESSAGES: What is already known on this topic: The numbers of mpox cases among men who have sex with men (MSM) in the Netherlands were low in 2023-2024, but there have been many introductions of new cases infected outside the Netherlands. Therefore, there are concerns about future mpox outbreaks, but it is uncertain whether new mpox vaccination campaigns are needed. What this study adds: Due to behavioural changes, not-immune MSM enter the group with high sexual activity, thus reducing the fraction immune within the group and increasing the possibility of future mpox outbreaks. Preventive mpox vaccination and behavioural adaptations can impede mpox spread. However, outbreak sizes will increase as the time between vaccination roll-out and new introductions is extended. How this study might affect research, practice or policy: Social marketing and interventions promoting timely behavioural changes and vaccination are essential. Recurring vaccination campaigns are necessary for mpox prevention, prioritising individuals with high sexual activity level and ensuring those entering high-activity groups are reached. The findings also emphasize that research is needed to understand determinants of behaviour and monitor behavioural changes over time.
Open AccessCombining mpox vaccination and behavioural changes to control possible future mpox resurgence among men who have sex with men: a mathematical modelling study
Introduction: The 2022 outbreak of mpox subclade IIb in the Netherlands affected primarily men who have sex with men (MSM). Despite the sharp decline in cases, there are concerns about future mpox outbreaks. We investigated the impact of mpox introductions, accounting for vaccination, behavioural changes, and introductions of subclades with different characteristics. Methods: We developed a compartmental model for mpox among MSM. We distinguished three levels of sexual activity: low, medium, and high. The group with high activity was the 5% of the population with the highest numbers of sexual partners; the group with low activity was the 60% with the lowest numbers of partners. In the model, individuals were allowed to change sexual activity level. We examined several scenarios with mpox introductions. Results: In January 2024, 54% of MSM with high sexual activity level had immunity; this declined to 39% a year later, due to changes in sexual activity. Introduction of 5 cases in May 2025 resulted in 759 cases in the first four months without vaccination after 2023, but the numbers of cases were 34% or 48% lower with 3,000 vaccinations in August-October 2024 or February-April 2025, respectively. With earlier initiation or greater magnitude of behavioural adaptations, the number of mpox cases was 17-51% smaller. Introduction of a subclade with 10% higher transmission probability than subclade IIb resulted in 77% more cases. Conclusions: Due to changes in sexual activity, the fraction immune in the group with high sexual activity will decline, leading to greater possibilities for future mpox outbreaks. The number of cases can be reduced with preventive vaccination and behavioural adaptations. Recurring vaccination campaigns should prioritise individuals with high sexual activity level, ensuring those entering high-activity groups are reached. Campaigns promoting timely behavioural changes remain crucial. KEY MESSAGES: What is already known on this topic: The numbers of mpox cases among men who have sex with men (MSM) in the Netherlands were low in 2023-2024, but there have been many introductions of new cases infected outside the Netherlands. Therefore, there are concerns about future mpox outbreaks, but it is uncertain whether new mpox vaccination campaigns are needed. What this study adds: Due to behavioural changes, not-immune MSM enter the group with high sexual activity, thus reducing the fraction immune within the group and increasing the possibility of future mpox outbreaks. Preventive mpox vaccination and behavioural adaptations can impede mpox spread. However, outbreak sizes will increase as the time between vaccination roll-out and new introductions is extended. How this study might affect research, practice or policy: Social marketing and interventions promoting timely behavioural changes and vaccination are essential. Recurring vaccination campaigns are necessary for mpox prevention, prioritising individuals with high sexual activity level and ensuring those entering high-activity groups are reached. The findings also emphasize that research is needed to understand determinants of behaviour and monitor behavioural changes over time.
- Open Access
- 9 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0311114
Barriers and enablers that influence the uptake of HIV testing among heterosexual migrants in the Netherlands
Background: Heterosexual migrant men and women in the Netherlands often face barriers to accessing health services, including HIV testing, that may lead to late-stage HIV diagnoses. This study explored factors of influence in the usage of HIV testing among heterosexual migrants. Methods: Qualitative evaluation with semi-structured interviews at the Amsterdam-based AIDS Healthcare Foundation (AHF) Checkpoint and one focus group discussion (FGD) conducted during June-July 2023 with 19 participants: interviews with 12 heterosexual migrants from low- or middle-income countries (LMICs) and FGD (n = 5) and interviews (n = 2) with 7 key informants from the (public) health sector. Recorded interviews were transcribed and thematically analyzed, using the framework of Andersen’s Expanded Behavioral Model of Health Services Use. Results: In total, 55 themes emerged from the interviews and the FGD. Examples include insufficient availability of information on HIV and testing services, and difficulty in accessing these services (e.g. the barrier of the online appointment system of the Centre for Sexual Health (CSH)). HIV test participants expressed free, rapid testing, no appointment required, and a positive experience during their HIV test as enablers to test in the future. Results from key informants showed that poor health literacy and lack of clarity on the healthcare system’s guidelines were barriers for heterosexual migrants in accessing information on HIV and testing services. It also revealed past initiatives and interventions that were successful in reaching at-risk groups such as the integration of HIV testing into sexually transmitted infection (STI) testing, but that were subsequently discontinued due to financial constraints. Conclusion: Factors contributing to a low HIV test uptake were participants’ perception of limited accessibility of CSH facilities, insufficient available information on HIV (testing) services, and low perception of HIV risk. Unclear policies on accessing HIV/STI testing services at CSHs, and potential missed opportunities for HIV testing at general practitioners were contributing factors identified by key informants.
- 9 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0311114
Open AccessBarriers and enablers that influence the uptake of HIV testing among heterosexual migrants in the Netherlands
Background: Heterosexual migrant men and women in the Netherlands often face barriers to accessing health services, including HIV testing, that may lead to late-stage HIV diagnoses. This study explored factors of influence in the usage of HIV testing among heterosexual migrants. Methods: Qualitative evaluation with semi-structured interviews at the Amsterdam-based AIDS Healthcare Foundation (AHF) Checkpoint and one focus group discussion (FGD) conducted during June-July 2023 with 19 participants: interviews with 12 heterosexual migrants from low- or middle-income countries (LMICs) and FGD (n = 5) and interviews (n = 2) with 7 key informants from the (public) health sector. Recorded interviews were transcribed and thematically analyzed, using the framework of Andersen’s Expanded Behavioral Model of Health Services Use. Results: In total, 55 themes emerged from the interviews and the FGD. Examples include insufficient availability of information on HIV and testing services, and difficulty in accessing these services (e.g. the barrier of the online appointment system of the Centre for Sexual Health (CSH)). HIV test participants expressed free, rapid testing, no appointment required, and a positive experience during their HIV test as enablers to test in the future. Results from key informants showed that poor health literacy and lack of clarity on the healthcare system’s guidelines were barriers for heterosexual migrants in accessing information on HIV and testing services. It also revealed past initiatives and interventions that were successful in reaching at-risk groups such as the integration of HIV testing into sexually transmitted infection (STI) testing, but that were subsequently discontinued due to financial constraints. Conclusion: Factors contributing to a low HIV test uptake were participants’ perception of limited accessibility of CSH facilities, insufficient available information on HIV (testing) services, and low perception of HIV risk. Unclear policies on accessing HIV/STI testing services at CSHs, and potential missed opportunities for HIV testing at general practitioners were contributing factors identified by key informants.
- Open Access
- 19 September 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (38) , 2400083
Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022
Background: In the Netherlands, HIV pre-exposure prophylaxis (PrEP) has been available since 2019. However, the extent of PrEP use prior to HIV diagnosis and development of PrEP-resistance-associated mutations (RAMs) is not known. Aim: We assessed prior PrEP use and potential transmission of PrEP RAMs among men who have sex with men (MSM) and transgender persons (TGP) with a new HIV diagnosis in the Netherlands. Methods: Data on prior PrEP use between 1 January 2018 and 31 December 2022 were available from the Dutch national ATHENA cohort. We assessed proportion of prior PrEP use, detected PrEP associated RAMs and assessed potential onward transmission of RAMs between 2010 and 2022 using a maximum likelihood tree. Results: Data on prior PrEP use were available for 583/1,552 (36.3%) individuals, with 16% (94/583) reporting prior PrEP use. In 489 individuals reporting no prior PrEP use, 51.5% did not use PrEP due to: low HIV-risk perception (29%), no access (19.1%), personal preference (13.1%), and being unaware of PrEP (19.1%). For PrEP users, 13/94 (13.8%) harboured a M184V/I mutation, of whom two also harboured a K65R mutation. In people with a recent HIV infection, detection of PrEP RAMs increased from 0.23% (2/862) before 2019 to 4.11% (9/219) from 2019. We found no evidence of onward transmission of PrEP RAMs. Conclusion: The prevalence of PrEP-associated RAMs has increased since PrEP became available in the Netherlands. More widespread access to PrEP and retaining people in PrEP programmes when still at substantial risk is crucial to preventing new HIV infections.
- 19 September 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (38) , 2400083
Open AccessOral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022
Background: In the Netherlands, HIV pre-exposure prophylaxis (PrEP) has been available since 2019. However, the extent of PrEP use prior to HIV diagnosis and development of PrEP-resistance-associated mutations (RAMs) is not known. Aim: We assessed prior PrEP use and potential transmission of PrEP RAMs among men who have sex with men (MSM) and transgender persons (TGP) with a new HIV diagnosis in the Netherlands. Methods: Data on prior PrEP use between 1 January 2018 and 31 December 2022 were available from the Dutch national ATHENA cohort. We assessed proportion of prior PrEP use, detected PrEP associated RAMs and assessed potential onward transmission of RAMs between 2010 and 2022 using a maximum likelihood tree. Results: Data on prior PrEP use were available for 583/1,552 (36.3%) individuals, with 16% (94/583) reporting prior PrEP use. In 489 individuals reporting no prior PrEP use, 51.5% did not use PrEP due to: low HIV-risk perception (29%), no access (19.1%), personal preference (13.1%), and being unaware of PrEP (19.1%). For PrEP users, 13/94 (13.8%) harboured a M184V/I mutation, of whom two also harboured a K65R mutation. In people with a recent HIV infection, detection of PrEP RAMs increased from 0.23% (2/862) before 2019 to 4.11% (9/219) from 2019. We found no evidence of onward transmission of PrEP RAMs. Conclusion: The prevalence of PrEP-associated RAMs has increased since PrEP became available in the Netherlands. More widespread access to PrEP and retaining people in PrEP programmes when still at substantial risk is crucial to preventing new HIV infections.
- Open Access
Effects of Improved Partner Notification on the Transmission of HIV and N. Gonorrhoea Among Men Who Have Sex With Men: A Modelling Study
Men who have sex with men (MSM) are disproportionally affected by HIV in the Netherlands. Partner Notification (PN) is an important element of controlling the transmission of sexually transmitted infections (STIs) and HIV. We investigated the effects of improving PN on the transmission of HIV and N. gonorrhoeae (NG) among MSM in the Netherlands. We developed an agent-based model that describes the transmission of HIV and NG among MSM. In the baseline scenario 14.3% and 29.8% of casual and steady partners of the index case get notified and tested for HIV/STI after three weeks (percentage notified and tested, PNT). We examined the following scenarios: 1) Increase PNT to 41% for both partner types; 2) Decrease the time between index and the partners tested to one week; 3) Combine scenario 1 and 2. Effects are expressed as cumulative change from the baseline simulation over 15 years. Increasing PNT could lead to a decrease in gonorrhea cases of 45% (IQR: 39.9 – 49.9%), with an increase in number of HIV/STI tests of 4.4% (IQR: 1.6 – 7.3%), but no change in HIV infections (−5.4%; IQR: -21 – 7.9%). Decreasing time between tests could lead to a change in new NG infections of -14.2% (IQR: -17.2 – -10%), no change in HIV infections (8.2%; IQR: - 1.3 – 20%) or in number of HIV/STI tests performed (−0.4%; IQR: - 1.5 – 0.6%). Scenario 3 led to a change in NG infections of -56.8% (IQR: - 63.8 – - 47.4%), no change in HIV infections (11.5%; IQR: -11.1 – 33.9%) or in number of HIV/STI tests (− 0.5%; IQR: - 4.9 – 4.3%). Increasing the percentage of sexual partners notified and tested for HIV/STI may have only a small effect on HIV, but could reduce the number of new NG infections substantially. However, it could lead to an increase in the number of HIV/STI tests performed. Key messages What is already known on this topic: Notifying recent sexual partners of people diagnosed with HIV or other sexually transmitted infections (STI) can promote timely testing and early treatment, thereby reducing further transmission of STIs What this study adds: We quantify the effects of improving partner notification on the transmission of two STIs simultaneously. How this study might affect research, practice or policy: In our scenarios, increasing the percentage of partners who get notified and tested had a bigger impact than decreasing the time between testing the index and his partners.
Open AccessEffects of Improved Partner Notification on the Transmission of HIV and N. Gonorrhoea Among Men Who Have Sex With Men: A Modelling Study
Men who have sex with men (MSM) are disproportionally affected by HIV in the Netherlands. Partner Notification (PN) is an important element of controlling the transmission of sexually transmitted infections (STIs) and HIV. We investigated the effects of improving PN on the transmission of HIV and N. gonorrhoeae (NG) among MSM in the Netherlands. We developed an agent-based model that describes the transmission of HIV and NG among MSM. In the baseline scenario 14.3% and 29.8% of casual and steady partners of the index case get notified and tested for HIV/STI after three weeks (percentage notified and tested, PNT). We examined the following scenarios: 1) Increase PNT to 41% for both partner types; 2) Decrease the time between index and the partners tested to one week; 3) Combine scenario 1 and 2. Effects are expressed as cumulative change from the baseline simulation over 15 years. Increasing PNT could lead to a decrease in gonorrhea cases of 45% (IQR: 39.9 – 49.9%), with an increase in number of HIV/STI tests of 4.4% (IQR: 1.6 – 7.3%), but no change in HIV infections (−5.4%; IQR: -21 – 7.9%). Decreasing time between tests could lead to a change in new NG infections of -14.2% (IQR: -17.2 – -10%), no change in HIV infections (8.2%; IQR: - 1.3 – 20%) or in number of HIV/STI tests performed (−0.4%; IQR: - 1.5 – 0.6%). Scenario 3 led to a change in NG infections of -56.8% (IQR: - 63.8 – - 47.4%), no change in HIV infections (11.5%; IQR: -11.1 – 33.9%) or in number of HIV/STI tests (− 0.5%; IQR: - 4.9 – 4.3%). Increasing the percentage of sexual partners notified and tested for HIV/STI may have only a small effect on HIV, but could reduce the number of new NG infections substantially. However, it could lead to an increase in the number of HIV/STI tests performed. Key messages What is already known on this topic: Notifying recent sexual partners of people diagnosed with HIV or other sexually transmitted infections (STI) can promote timely testing and early treatment, thereby reducing further transmission of STIs What this study adds: We quantify the effects of improving partner notification on the transmission of two STIs simultaneously. How this study might affect research, practice or policy: In our scenarios, increasing the percentage of partners who get notified and tested had a bigger impact than decreasing the time between testing the index and his partners.
- Open Access
- 26 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Modelling the effectiveness of an isolation strategy for managing mpox outbreaks with variable infectiousness profiles
The global outbreak of mpox in 2022 and subsequent sporadic outbreaks in 2023 highlighted the importance of nonpharmaceutical interventions such as case isolation. Individual variations in viral shedding dynamics may lead to either premature ending of isolation for infectious individuals, or unnecessarily prolonged isolation for those who are no longer infectious. Here, we developed a modeling framework to characterize heterogeneous mpox infectiousness profiles – specifically, when infected individuals cease to be infectious – based on viral load data. We examined the potential effectiveness of three different isolation rules: a symptom-based rule (the current guideline in many countries) and rules permitting individuals to stop isolating after either a fixed duration or following tests that indicate that they are no longer likely to be infectious. Our analysis suggests that the duration of viral shedding ranges from 23 to 50 days between individuals. The risk of infected individuals ending isolation too early was estimated to be 8.8% (95% CI: 6.7–10.5) after symptom clearance and 5.4% (95% CI: 4.1–6.7) after 3 weeks of isolation. While these results suggest that the current standard practice for ending isolation is effective, we found that unnecessary isolation following the infectious period could be reduced by adopting a testing-based rule.
- 26 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Open AccessModelling the effectiveness of an isolation strategy for managing mpox outbreaks with variable infectiousness profiles
The global outbreak of mpox in 2022 and subsequent sporadic outbreaks in 2023 highlighted the importance of nonpharmaceutical interventions such as case isolation. Individual variations in viral shedding dynamics may lead to either premature ending of isolation for infectious individuals, or unnecessarily prolonged isolation for those who are no longer infectious. Here, we developed a modeling framework to characterize heterogeneous mpox infectiousness profiles – specifically, when infected individuals cease to be infectious – based on viral load data. We examined the potential effectiveness of three different isolation rules: a symptom-based rule (the current guideline in many countries) and rules permitting individuals to stop isolating after either a fixed duration or following tests that indicate that they are no longer likely to be infectious. Our analysis suggests that the duration of viral shedding ranges from 23 to 50 days between individuals. The risk of infected individuals ending isolation too early was estimated to be 8.8% (95% CI: 6.7–10.5) after symptom clearance and 5.4% (95% CI: 4.1–6.7) after 3 weeks of isolation. While these results suggest that the current standard practice for ending isolation is effective, we found that unnecessary isolation following the infectious period could be reduced by adopting a testing-based rule.
- Open Access
- 13 December 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 36, 100792
Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis
- 13 December 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 36, 100792
Open AccessPrevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis